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Sir,
We thank Thomas et al (2009) for their thorough collection and
presentation of resource use and costs for breast cancer relapse.
This represents an excellent summary of the costs of advanced
breast cancer to the NHS. Current data of this kind is vital for
NICE to make decisions based on robust evidence. Detailed
inclusion of community costs make this study one of the most
comprehensive cost descriptions for advanced breast cancer in the
United Kingdom to date. Publication of cost data for the
management of cancer in peer-reviewed journals is an important
priority for the future. We would like to communicate a need for
caution and clarity of direction in how these data are developed.
The authors identified increasing overall treatment costs as a
consequence of the introduction of new and expensive targeted
therapies such as trastuzumab (Herceptin). The costs for the one-
fifth of patients whose tumours overexpress HER2 were suggested
to be higher than for other patients. This is an important issue, as
there is now good evidence that the biological subgroups of breast
cancer have very different characteristics and prognosis (Perou
et al, 2000; Dent et al, 2008). Global clinical trials of new therapies
are now looking at these subgroups separately. This will result in
very different treatment pathways with differences in resource use
and costs and a consequent influence on cost-effectiveness results.
Thomas et al (2009) present their cost analysis with a view to
future economic evaluation of new targeted therapies for early
breast cancer. In addition to calculating a monthly cost per patient
from relapse, it would be useful to consider costs, which arise prior
to relapse. For example, certain subgroups may accrue more costs
due to side effects from adjuvant therapy before relapse, with a
lower monthly cost after relapse compared with other subgroups.
Proximity to death (i.e., life expectancy at cancer relapse) has
been identified as a predictor of healthcare expenditure (Shang
and Goldman, 2007). It is likely to vary significantly between
subgroups and should be reported in relation to costs. It would
also be interesting to evaluate the relationship between distribu-
tion of costs (community care vs hospital) and proximity to death,
or death itself. This would give us important information
regarding patterns of resource utilization, which could then be
used for more insightful service planning.
There is therefore a real need for future cost analyses in breast
cancer and other cancers to differentiate between biological
subgroups. This need is amplified when considering the cost
implications of adjuvant therapies specifically targeting these
subgroups. Future studies must be larger, with adequate numbers
in each subgroup, or be more specifically focused on a single
subgroup to provide adequately powered results. Standards must
be adopted at a national level for independently collecting
subgroup data as malignant diseases become further divided by
gene expression profiling with individualised treatment options.
Cost analyses such as Thomas et al (2009) have provided,
represent a first step in this direction and are invaluable in
providing evidence for increasingly difficult decisions.
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